SAN DIEGO and TORONTO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly ...
Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults affecting 2-6 adults per 100,000k globally. With relapse rates as high as 50%, routine measurable residual disease (MRD) ...
Allo-HSCT significantly improved survival in real-world pediatric AML, with CR1 patients showing the best outcomes, achieving OS and DFS rates of 84.2% and 73.4%. Matched sibling and unrelated donors ...
I'm initiating SELLAS Life Sciences (SLS) with a "Hold" rating. The reason why I'm giving this biotech this rating is because it is in the process of developing its WT1-targeting immunotherapeutic ...
Kura Oncology ((KURA)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...
— OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients — SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results